Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Felicitas Hitz"'
Autor:
Murielle Lalive d’Epinay, Sabine Güsewell, Nicole Graf, Ulrich J. M. Mey, Christoph Driessen, Felicitas Hitz
Publikováno v:
Hematological Oncology. 40:716-723
Major improvements in outcome of older patients with multiple myeloma (MM) have been achieved with the introduction of novel agents. Their impact in real-life treatment of older patients is unclear. In this single center retrospective study, we analy
Autor:
Emanuele Zucca, Natalie Fischer, Felicitas Hitz, A Schmidt, C Pfleger, C Caspar, S Güsewell, M. Fehr, M Rütti, Frank Stenner, Michèle Voegeli, Alden A. Moccia, Fatime Krasniqi, Ulrich Mey, Mario Bargetzi, Guido Ghilardi, P Richter, W. Mingrone, N Lang, Thilo Zander, S. Aeppli, D. Brülisauer, M Ebnöther, Urban Novak
Publikováno v:
Hematological Oncology. 39:196-204
Hodgkin lymphoma (HL) in older patients appears to be a different disease compared with younger patients with historically lower survival rates. This is related to a variety of factors, including increased treatment-related toxicity, the presence of
Autor:
Anastasios Stathis, Ulrich Mey, Sämi Schär, Felicitas Hitz, Christiane Pott, Nicolas Mach, Fatime Krasniqi, Urban Novak, Christian Schmidt, Karin Hohloch, Dirk Lars Kienle, Dagmar Hess, Alden A. Moccia, Michael Unterhalt, Katrin Eckhardt, Stefanie Hayoz, Gabriela Forestieri, Davide Rossi, Stefan Dirnhofer, Luca Ceriani, Giulio Sartori, Francesco Bertoni, Christian Buske, Emanuele Zucca, Wolfgang Hiddemann
This phase 1 study evaluated safety, tolerability, and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two DLs of venetoclax were ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd4f5ea053fe49750db60517bc3aca74
Autor:
Lutz van Heek, Colin Stuka, Helen Kaul, Horst Müller, Jasmin Mettler, Felicitas Hitz, Christian Baues, Michael Fuchs, Peter Borchmann, Andreas Engert, Markus Dietlein, Conrad-Amadeus Voltin, Carsten Kobe
Publikováno v:
BMC cancer. 22(1)
Background 18F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total
Autor:
Felicitas Hitz, Maria Cristina Pirosa, D. Hess, Anastasios Stathis, Francesco Bertoni, Lu Zhang, Urban Novak, Mariarosa Pascale, Tatiana Terrot, Emanuele Zucca, Franco Cavalli, Luca Mazzucchelli
Publikováno v:
Leukemialymphoma. 63(1)
This phase I trial evaluated the safety, tolerability, and preliminary activity of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed/refractory CD22 positive B-cell non-Hodgkin lymphomas. Nineteen patients received at l
Autor:
Steven M. Horwitz, Julie M. Vose, Ivan Dlouhy, Silvia Montoto, Andrei R. Shustov, Tetiana Skrypets, Umberto Vitolo, Maria Elena Cabrera, José Vassallo, Ranjana H. Advani, Michael A. Spinner, Massimo Federico, Stefano Pileri, Monica Civallero, Won Seog Kim, Martina Manni, Giorgio Inghirami, Felicitas Hitz, John Radford
Publikováno v:
Blood
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018 in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b9f6f2f5b8072196400dffdc77bd2e
https://europepmc.org/articles/PMC8493974/
https://europepmc.org/articles/PMC8493974/
Autor:
Simona Berardi Vilei, Andreas Lohri, Mario Bargetzi, Ulrich Mey, Micaela Hernberg, Stefan Dirnhofer, Thilo Zander, Ann-Sofie Johansson, Peter de Nully Brown, Walter Mingrone, Eva Kimby, Bjørn Østenstad, Urban Novak, Daniel Rauch, Björn E. Wahlin, Fatime Krasniqi, Felicitas Hitz, Emanuele Zucca, Michele Ghielmini, Stefanie Hayoz, Hans Hagberg, Hanne Skjerven Bersvendsen, Hanne Hawle, Andrés J.M. Ferreri, Anna Vanazzi, Stephanie Rondeau
Publikováno v:
Blood. 134:353-362
The SAKK 35/10 phase 2 trial, developed by the Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group, compared the activity of rituximab vs rituximab plus lenalidomide in untreated follicular lymphoma patients in need of systemic the
Autor:
Alessio Bruscaggin, Francesco Passamonti, Thomas Tousseyn, Anna Guidetti, Luca Ceriani, Paolo Corradini, Francesco Piazza, Carlos Montalbán, Adalgisa Condoluci, Marco Bühler, Giorgio A. Vanini, Lodovico Terzi di Bergamo, M. Faderl, Urban Novak, Miguel A. Piris, Luisella Bonomini, Elena Sabattini, Liliana Devizzi, Govind Bhagat, Carlo Visco, Fabio Facchetti, Arianna Calcinotto, Francesca Guidetti, M. Ladetto, Umberto Vitolo, Francesco Bertoni, Armando López-Guillermo, Giuseppe Gritti, Thorsten Zenz, Valeria Spina, Renata Walewska, Marco Paulli, Julia T. Geyer, David Oscier, Catherine Thieblemont, Estella Matutes, Francesco Zaja, Elisa Lucchini, Alexandra Traverse-Glehen, Guido Ghilardi, Emanuele Zucca, Alberto J. Arribas, Renzo Boldorini, Marco Lucioni, Pier Luigi Zinzani, K. Pini, Alden A. Moccia, Stefano Pileri, Alexander Tzankov, Wu Wei, Angela Rita Elia, Maria Joao Baptista, Lydia Scarfò, Stefan Dirnhofer, Laurence de Leval, Sílvia Beà, Gabriela Bastidas, Alessandra Tucci, Giorgio Inghirami, Gianluca Gaidano, Gilles Salles, Felicitas Hitz, Enrico Derenzini, Gustavo Tapia, Ferdinando Bonfiglio, Alessandro Broccoli, Micol Giulia Cittone, Sascha Dietrich, Luca Arcaini, Paolo Ghia, Hossein Khiabanian, Michele Merli, Alessandro Rambaldi, Manuela Mollejo, Maria Cristina Pirosa, Deborah Piffaretti, Anastasios Stathis, Antonino Maiorana, Ricardo Koch, Juan F. García, Sergio Cogliatti, Gabriela Forestieri, Roberto Marasca, Stefano Pizzolitto, Elisa Santambrogio, Georg Stussi, Maurilio Ponzoni, Bernhard Gerber, Maria Gomes da Silva, Corrado Tarella, Luciano Cascione, Elias Campo, Luca Mazzucchelli, Davide Rossi, Véronique Meignin, Vincenzo Canzonieri, Franco Cavalli
Publikováno v:
Blood
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Bonfiglio, Ferdinando; Bruscaggin, Alessio; Guidetti, Francesca; Terzi di Bergamo, Lodovico; Faderl, Martin Richard; Spina, Valeria; Condoluci, Adalgisa; Bonomini, Luisella; Forestieri, Gabriela; Koch, Ricardo; Piffaretti, Deborah; Pini, Katia; Pirosa, Maria C; Cittone, Micol Giulia; Arribas, Alberto; Lucioni, Marco; Ghilardi, Guido; Wu, Wei; Arcaini, Luca; Baptista, Maria Joao; ... (2022). Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. Blood, 139(5), pp. 732-747. American Society of Hematology 10.1182/blood.2021012386
Blood, vol. 139, no. 5, pp. 732-747
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Bonfiglio, Ferdinando; Bruscaggin, Alessio; Guidetti, Francesca; Terzi di Bergamo, Lodovico; Faderl, Martin Richard; Spina, Valeria; Condoluci, Adalgisa; Bonomini, Luisella; Forestieri, Gabriela; Koch, Ricardo; Piffaretti, Deborah; Pini, Katia; Pirosa, Maria C; Cittone, Micol Giulia; Arribas, Alberto; Lucioni, Marco; Ghilardi, Guido; Wu, Wei; Arcaini, Luca; Baptista, Maria Joao; ... (2022). Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. Blood, 139(5), pp. 732-747. American Society of Hematology 10.1182/blood.2021012386
Blood, vol. 139, no. 5, pp. 732-747
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84cc3c9dea90557598dbad050fac76c1
Autor:
Hans Theodor Eich, Andreas Engert, Bernd Hertenstein, Felicitas Hitz, Walter E. Aulitzky, Peter Borchmann, Harald Stein, Michael Fuchs, Hans-Joachim Beck, Martin Bentz, Markus Dietlein, Julia Meissner, Max S. Topp, Helen Goergen, Ina Buehnen, Dennis A. Eichenauer, Carsten Kobe, Richard Greil, Jana Markova, Thomas Pabst, Wolfgang Willenbacher, Alden A. Moccia, Christian Baues, Martin Soekler, Helmut Ostermann, Volker Diehl, Georg Maschmeyer, Wolf-Dieter Ludwig, Dagmar Kühnhardt, Ulrich Keller, Tom Vieler, Stefanie Kreissl, Michaela Feuring-Buske, Josée M. Zijlstra
Publikováno v:
German Hodgkin Study Group 2021, ' PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial ', Lancet haematology, vol. 8, no. 6, pp. e398-e409 . https://doi.org/10.1016/S2352-3026(21)00101-0
Lancet haematology, 8(6), e398-e409. Lancet Publishing Group
Lancet haematology, 8(6), e398-e409. Lancet Publishing Group
Summary Background The German Hodgkin Study Group's HD18 trial established the safety and efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) for the trea
Autor:
Martina Manni, Raul Gabus, Seok Jin Kim, Ivan Dlouhy, Young Hyeh Ko, Giorgio Inghirami, Felicitas Hitz, Andrei R. Shustov, Carlos S. Chiattone, Massimo Federico, Steven M. Horwitz, Stefano Pileri, Monica Civallero, Virginia Martinez, Won Seog Kim, Arnon Nagler, Tetiana Skrypets, Michele Spina, Maria Elena Cabrera, Silvia Montoto, Carmino Antonio De Souza, Veronika Ballova, Ruben Fernandez-Alvarez, Christopher P. Fox
Summary Background Extranodal natural killer (NK) T-cell lymphoma (ENKTL) is a unique clinicopathological entity, typically associated with poor survival outcomes. Most published data have come from east Asian study groups, with little information av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2477348b61d3c99a0017860bcfe68564
https://hdl.handle.net/11380/1201650
https://hdl.handle.net/11380/1201650